Fate Therapeutics, Inc. (FATE)
$2.454
Rating:
Recommendation:
Neutral
| Symbol | FATE |
|---|---|
| Price | $2.454 |
| Beta | 1.459 |
| Volume Avg. | 2.19M |
| Market Cap | 241.969M |
| Shares () | - |
| 52 Week Range | 1.63-21.47 |
| 1y Target Est | - |
| DCF Unlevered | FATE DCF -> | |
|---|---|---|
| DCF Levered | FATE LDCF -> | |
| ROE | -34.50% | Strong Sell |
| ROA | -28.58% | Sell |
| Operating Margin | - | |
| Debt / Equity | 26.06% | Neutral |
| P/E | -1.39 | Sell |
| P/B | 0.60 | Buy |
Latest FATE news
About
Download (Excel)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.